# Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct07107217/  
OnCo record `nct07107217` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, doxorubicin, cyclophosphamide, carboplatin and other drugs in triple-negative breast cancer, run by Blokhin's Russian Cancer Research Center, not yet recruiting.

## Summary

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT07107217 by Blokhin's Russian Cancer Research Center, with a registry enrolment figure of 40 participants, started 2025-08 and due to reach its primary completion in 2026-12. Interventions recorded: Camrelizumab; Doxorubicin +cyclophosphamide+ filgrastimum; carboplatin + paclitaxel (CP). Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "1\) 18-65 Years, female; 2) Histologically documented Triple Negative Breast Cancer (TNBC) patients; 3) Previously untreated non-metastatic (M0) TNBC, T3-4NanyM0 или TanyN+M0 3) Promising radical surgical treatment; 4) At least one measurable lesion according to RECIST 1". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: Camella
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07107217
- Phase: 2
- Setting: Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer
- Sponsor: Blokhin's Russian Cancer Research Center
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07107217: https://clinicaltrials.gov/study/NCT07107217

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07107217.json